Clinical trial · Observational
Family History in a Singaporean Healthy Population
Integration of Family Health History Data Into a Singaporean Healthy Population Cohort Database to Understand the Associations Between Family Health History and Genomics
NCT03114553CI-TRIAL-00085688completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to better understand the linkages between family health history (FHH) and genomics in a Singaporean population. Secondly this study will evaluate the facilitators and barriers to implementation of a family history collection and risk assessment tool within a Singaporean population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| All | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MeTree | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation of genomic data and family health history (FHH) within a healthy Asian population.
- timeFrame
- Baseline
- description
- assess whether family history driven risk results correlate with findings on genetic results
Secondary outcomes (2)
- measure
- Clinical utility and appropriateness of a patient-entered FHH risk assessment tool within a Singaporean population
- timeFrame
- Baseline
- description
- Determine whether US guideline driven risk assessment has any clinical value in Singapore
- measure
- Facilitators and barriers to using systemic risk assessment tool in Singapore
- timeFrame
- Baseline
- description
- Identify facilitators and barriers to using risk assessment tool in order to create a strategy for broader implementation of a patient-driven risk assessment tool in Singapore
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy Singaporeans enrolled or eligible for enrollment in a local Biobank protocol Exclusion Criteria: \-
References
Publications (2)
- BACKGROUNDWu RR, Sultana R, Bylstra Y, Jamuar S, Davila S, Lim WK, Ginsburg GS, Orlando LA, Yeo KK, Cook SA, Tan P. Evaluation of family health history collection methods impact on data and risk assessment outcomes. Prev Med Rep. 2020 Mar 5;18:101072. doi: 10.1016/j.pmedr.2020.101072. eCollection 2020 Jun. PMID 32181122
- RESULTBylstra Y, Lim WK, Kam S, Tham KW, Wu RR, Teo JX, Davila S, Kuan JL, Chan SH, Bertin N, Yang CX, Rozen S, Teh BT, Yeo KK, Cook SA, Jamuar SS, Ginsburg GS, Orlando LA, Tan P. Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Med. 2021 Jan 7;13(1):3. doi: 10.1186/s13073-020-00819-1. PMID 33413596